SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
Hozirda 2-bosqich asosiy sinovida tekshirilayotgan CART-ddBCMA - bu Arcellx kompaniyasining yangi sintetik bog'lovchi D-Domaindan foydalangan holda T-hujayra terapiyasi. Kite va Arcellx birgalikda CART-ddBCMA aktivini AQShda ilgari suradi va tijoratlashtiradi, Kite esa mahsulotni AQShdan tashqarida tijoratlashtiradi.
CAR T-Cell terapiyasi qon saratonining ayrim turlarini davolashning yutuq usullaridan biridir. 750 dan ortiq davom etmoqda klinik tadqiqotlar in Xitoyda CAR T-Cell terapiyasi ayni paytda. Ro'yxatdan o'tishni hohlagan bemorlar murojaat qilishlari mumkin Saraton kasalligi WhatsApp-da bemorlarning ishonch telefoni + 91 96 1588 1588 yoki elektron pochta manziliga yuboring info@cancerfax.com.
Arcellx haqida
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory ko'p mieloma (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk miyelodisplastik sindrom, initiated in the fourth quarter of 2022.
Kite haqida
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply, and commercial product manufacturing.
Gilad ilmlari haqida
Gilead Sciences, Inc. biofarmatsevtika kompaniyasi bo'lib, u barcha odamlar uchun sog'lom dunyo yaratish maqsadini ko'zlagan holda o'ttiz yildan ortiq vaqt davomida tibbiyotda yutuqlarga erishgan va erishgan. Kompaniya hayot uchun xavfli kasalliklar, jumladan OIV, virusli gepatit va saratonni oldini olish va davolash uchun innovatsion dori vositalarini ilgari surish majburiyatini oladi. Gilad dunyoning 35 dan ortiq mamlakatlarida faoliyat yuritadi, bosh qarorgohi Kaliforniya shtati Foster shahrida joylashgan. Gilead Sciences Kite’ni 2017 yilda sotib olgan.
